Overview

Suvorexant for Opioid/Stimulant Co-use

Status:
Not yet recruiting

Trial end date:
2023-11-30

Target enrollment:
0

Participant gender:
All

Summary

This study will evaluate whether Suvorexant 20mg reduces drug use and craving, and improves sleep and stress among persons with co-occurring opioid use disorder and stimulant use disorder.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Johns Hopkins University

Treatments:

Orexin Receptor Antagonists
Suvorexant

Criteria

Inclusion Criteria:

1. Ages 18-65,

2. Meet criteria for stimulant use disorder, based on the Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR)

3. Currently receiving methadone or buprenorphine treatment for OUD and considered to be
stable on current dose for at least 30 days

4. Willingness to engage with study protocol

5. Use of birth control (as appropriate)

Exclusion criteria:

1. Psychiatric or medical conditions that are judged by the investigators to interfere
with participation or that are contraindicated for use with SUVO

2. Pregnant or breastfeeding

3. Current use of benzodiazepines, tranquilizers, or other schedule IV sleep medications

4. Moderate or severe substance use disorder other than opioid or stimulant use disorder

5. SUVO consumption in the last 30 days

6. Use of medications that are contraindicated with the study

7. Past 30-day suicidal behavior

8. Use of continuous positive airway pressure (CPAP) device for sleep apnea